This STZ-APP/PS1dual model is a newer approach to treating memory impairment in mice.The strategy combines previously used STZ-induced dementia and a geneticallymodified transgenic model.92 Hence, itcan be speculated that this model will generate a higher amount andresemblance of AD features and can be synergistic compared to individualSTZ or APP/PS1 models. This evidence concerns the gene APP and Alzheimer disease.